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Prostaglandin and Leukotriene Synthesis in Mouse Ears Inflamed by 
Arachidonic Acid* 
EVAN E. 0PAS, M.S., ROBERT J. BONNEY, P H.D ., AND JOHN L_ H UMES, PH -D. 
Department of Immunology, Merck Institute for Therapeutic Research, Rahway, New J ersey, U.S.A. 
Topical application of arachidonic acid on mouse ears 
induces the sy n thesis of prostaglandin E2 and leuko-
trienes c. and D 4 _ The increased tissue levels of these 
products a r e quantitated by radioimmunoassay _ The 
identity of the leukotrienes was confirmed by immuno-
reactivity of reverse-phase high-performance liquid 
chromatography fractions corresponding to authentic 
standards. Synthesis of the arachidonic acid metabolites 
precedes or is coincident with increased vascular perme-
ability resulting in an edematous response, as measured 
by accumulation of [l 25 l)albumin in the ear after i .v. 
injection or by tissue wet w eight. Whe n applied topi-
cally, anti-inflammatory drugs such as BW755C (3-
amino-1-(m-[trifluoromethyl]pheny l)2-py razoline, in-
domethacin, and nordihydroguaiaretic acid inhibit 
edema and modulate the appearance of the arachidonic 
acid products. The data suggest the coinvolvement of 
prostaglandin E 2 and leukotrienes c. a nd D. as media-
tors of inflammation in this in vivo model. 
The topical activi ty of inflammatory and ant i-inflammatory 
agents t hat modulate arachidonic acid (AA) metabolism can 
best be evaluated in an animal model of inflammat ion which 
measures direct ly t hose metabolites. Rodent ear edema can be 
induced by va rious stimuli including croton oil [1 ,2], phorbol 
myristate acetate [3], or AA [ 4,5). The resul tant edema can be 
measured, and agents that inhibit the edematous response are 
postulated to affect the biochemical mediators of inflammation 
wit hin t he t issue [2- 5). Prostaglandins and leukotrienes are 2 
classes of presumed mediators of inflammation (for review see 
[6)) produced by separate oxidative pathways of AA, cycloox-
ygenase and 5- lipoxygenase, respectively. Levels of prostaglan-
dins have been determined in mouse epidermis stimulated with 
phorbol esters [7- 9) but there has been hi therto no in vivo 
model wi t h which to measure products of both t he cyclooxygen-
ase and 5- lipoxygenase pat hways induced by topical stimuli. 
We show here t hat application of AA to mouse ears induces 
synthesis of both prostaglandin (PG) E2 and leukotrienes (L T ) 
C, and D . ., t he levels of which can be modulated by anti-
inflammatory agents. 
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Abbreviations: 
AA: arachidonic ac id 
BSA: bovine serum albumin 
BW755C: 3-amino- 1-(m-[t rifluoromethyl] phenyl)-2-pyrazoline 
HPLC: high perfo rmance liquid chromatography 
L T: leukotriene 
NDGA: nordihydroguaiaretic ac id 
PG: prostaglandin 
PMNL: polymorphonuclear leukocyte(s} 
RIA: radioimmunoassay 
TLC: t hin-layer chromatography 
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MATERIALS AND METHODS 
ChemicaL~ 
AA was purchased from Sigma Chemical Co., St. Louis, Missouri, or 
Nu Chek P rep., Inc., Elysian, Minnesota. Indomethacin and nordihy-
droguaiaretic acid (NDGA) were purchased from Sigma. 3-Amino-1-
(m-[t rifluoromethyl]phenyl}-2-pyrazoline (BW755C) was prepared by 
A. Tischler of Merck laborato ries. PGE2 was purchased from Ono 
P harmaceut ical Company, Ltd. , Osaka, J apan; LTC, and LTD, were 
provided by J Rokach, Merck-Frosst, Montreal, Can ada. PGE2 antisera 
were purchased from Miles Research P roducts, Elkhart, Indiana, and 
LTC, antisera were provided by E . C. Hayes of Merck laboratories. 
[5,6,8,11,12,14,15-3H(N)]PGE2 (100- 200 Ci/mmol) , (14,15-3H (N )] 
LTC, (20- 60 Ci/ mmol) , and [125I]albumin (bovine serum) (BSA) (1-
5mCi/mg) were purchased from New England Nuclear, Boston, Mas-
sachusetts. 
A nimals 
Female CD-1 outbred mice (4 - 6 weeks of age) were obtained from 
Charles River Breeding Laboratories, Kingston, New York, and main-
tained on standard pellet diet and water ad libitum. The mice were 
housed for 2 weeks prior to use. Five animals were used per group. 
Edema/Vascular Permeability M easurements 
AA was applied to the inside of the left ear of mice in 0.025 ml of a 
freshly prepared vehicle consisting of acetone:pyridine:water (97:2:1, 
v/v/ v) and dried with the use of a hand-held hair dryer. Except for 
dose-response studies, 0.5 mg AA was rout inely employed. Drugs were 
coapplied with AA. Animals were sacrificed by cervical dislocation and 
a 6 mm-diameter disc of tissue was removed from the ea r by means of 
a metal punch. Edema was measured by t he wet weight of this t issue. 
For determination of increased vascular permeabili ty [10], 0.002 mCi 
of [125l]BSA in 0.2 ml saline was injected into the tai l vein of mice at 
least 1 h prior to AA treatment. Influx of [125l) BSA was measured in 
tissue punches from both the t reated and un t reated ear by a Packard 
Auto-Gamma 800 counter. The comparison between edema and vas-
cular permeability measurements was excellent wit h a correlation 
coeffici ent of 0.86, and tests were used in te rchangeably. 
Biochem ical Meas urements 
Mouse ears destined for biochemical analysis of AA metabolites were 
t reated in the same manner as those for edema measurements. T issue 
punches from un t reated ears (pooled samples, n = 5) were placed 
immediately in to 1 ml ice-cold methanol in a Dual! glass t issue grinder 
(Kontes, Vineland, New Jersey) which was maintained at 4 ' C. J ust 
prior to homogenization, an equal volume of 0.1 M sodium acetate, pH 
4.2, was added and the t issue was homogenized by a motor-dr iven 
rotating glass pestle. The homogenate was cent rifuged for 10 min at 
12,000 g, 4 ' C. The supernatant was t ransferred to a clean glass tube 
and extracted twice with 6 ml freshly distilled diethyl ether. The ether 
phases were combined, washed once with 1 ml cold water , evaporated 
under nit rogen, and dissolved in 0.1 ml methanol. Thin-layer chroma-
tography (TLC) was performed with th is organic ext ract on alte rnate 
1-em la nes on Whatma n 20 X 20 em LD5DF silica gel plates developed 
w1th chloroform:methanol:glacial acetic acid:wate r (90:8:1:0.8). The 
prostaglandin zone of the chromatogram was removed, extracted with 
ether, and stored in methanol. The pept idoleukotrienes were parti-
tioned mto the aqueous phase of the original ether ext raction which 
was t hen removed afte r the second extraction and t ransferred to a glass 
tube conta ining 0.1 ml 7.5% sodium bicarbonate. This was evaporated 
dissolved in 0.5 ml water, loaded onto a prewashed C-18 Sep Pak 
cartridge (Waters Associates, Milford, Massachusetts) and washed with 
10 ml water. Peptidoleukot rienes were eluted wit h methanol and stored 
at -20'C unt il analysis. Radioimmunoassays (RIAs) were performed 
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ut ilizing the dextran -coated charcoal binding method as previously 
described [11] . Antisera against LTC, cross- reacted half as well with 
LTD, [12], and RIA determinations were defi ned as amounts of "L TC, j 
D,." The limit of detection was 10 pg. High-performance liquid chro-
matography (HPLC) was performed on a reverse phase (5 ~tm) Supel-
cosil LC-18 column (Supelco, Inc.) with methanol:water-glacial acetic 
acid (75:25:0.1, adjusted to pH 5.4 with NH,OH) at 1 ml / min, 34•c. 
The sensitivity of HPLC analysis was 10 ng. 
RESULTS 
Topical appl ication of AA induced increased vascu lar perme-
ability and edema in t he mouse ear (Fig 1). The edema was 
maximum between 30 min and 3 h after treatment with 0.5 mg 
AA per site (F ig 2). P roducts of the cyclooxygenase and 5-
lipoxygenase present in the ear were synthesized in response 
to AA t reatment a nd could be extracted from the tissue and 
quantitated by the methods described in this report. Efftciency 
of recovery determined by usin g tritium- labeled PGE2 and 
LTC, was 58% and 34%, respectively (3 experiments). Promi-
nent AA metaboli tes fou nd in the tissue were PGEz, LTC,, and 
LTD,, as measured by RIA. L TC,/D4 reach thei r maximum 
levels 15 min after treatment with 0.5 mg AA (Fig 3) which 
t hus precedes maximum edema. PGE2 levels were maximal at 
15- 30 min. At 15 min, PGE2 was found to be present at levels 
of 23.4 pmol/ea r biopsy ± SE of 4.6 pmol (compiled from 32 
experiments). L T C.JD, were present at 15 min after challenge 
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FIG 1. Edema (e) and increased vascular permeabil ity (0) in re-
sponse to va rying concentrations of AA at 1 h after topical application. 
Each point represents the mean of 5 ear punch measurements. The 
SEM was less than 10% for wet weights. Increased vascular permea-
bility is expressed as ratio: [125l]BSA in experimental ear (E) / [125l ]BSA 
in control ear (C). 
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FIG 2. Time course of edema (e) and [125l]BSA accumulation (0) 
in response to 0.5 mg AA. Each point represents the mean of 5 ear 
punch measurements. The SEM was less than 10% for wet weights. 
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FIG 3. Time course of PGE2 (0) and L TC,/D4 (0) synthesis in 
response to 0.5 mg AA. Amounts of PGE2 (•) and LTC4/ D, (e) 
synthesized in response to vehicle are shown at 15 min after application. 
Each point represents the mean of 2 experiments. Five t issue biopsies 
were combined and extracted for each experimental observation. 
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FIG 4. Leukotriene immunoreactivity resolved by HPLC. Pooled 
mouse ear extracts were chromatographed by HPLC as described in 
Materials and Methods. Fractions were collected and subjected to RIA 
with LTC, antisera. Data are expressed as pg equivalents of LTC, 
(LTD, cross-reacts half as well as LTC, [12]). Peaks are coincident 
with authentic standards. 
at leve ls of 6.0 pmol/ear biopsy ± 0.6 (35 expe riments). T hese 
values ret1ect substantial increases over vehicle-treated ears 
which when measured at 15 min after app lication contain 0.4 
± 0.1 pmol PGE2 and 0.4 ± 0.0 pmol L TC, j D, (23 experiments). 
The identity of LTC, and LTD, was further confirmed by 
comparison with authentic standards on HPLC and by RIA of 
HPLC fractions (Fig 4) . Approximately equal amounts of L T C4 
and LTD, were found (5 experiments). 
Several experiments attempted to find material immuno-
reactive with antisera for thromboxane B~, 6-keto-prostaglan-
din F, ., (the stable b reakdown product of prostacyclin), or 
L TB,, but levels of these metabolites were found to be minimal 
(less t han 1 pmol/ear biopsy) and were not focused upon in the 
remainder of t he study. HPLC was not successful in detection 
of "'-oxidation products of LTB,. Some LTB,-RIA cross-reac-
t ivity (2 % with 20-hydroxy-LTB,, against LTB, antisera [13]) 
with extracts from prostaglandin zone of TLC p lates suggested 
their presence (data not shown). Measurements by HPLC of 
products from other lipoxygenase pathways, e.g., 12- and 15-
hydroxyeicosatetraenoic acids, was confounded by the presence 
of these hydroxy fatty acids in the AA purchased from Sigma 
which was routinely employed in these experiments. That the 
AA and not its derivative hydroxy fatty acids was causal in the 
induction of the int1ammatory reaction was confirmed by sev-
eral experiments using either fresh ly prepared AA (purified on 
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a Waters s ilica-Sep Pak cartridge) or AA purchased from 
N uChek Prep, Inc. Both of t hese materials were analyzed by 
reverse-phase HPLC at t he time of t he experiments and found 
to contain negligible amounts of hydroxy fatty acids. 
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FIG 5. Inhibi t ion of PG E2 (•) , L TC,jD, (e), and edema/vascular 
permea bi lity (A) by: A, B W755C; B, indomethac in ; and C, NDGA. 
Representative experiments a re show n. Each point represents 5 com-
bined t issue biopsies. Vehicle contro l va lues were subt racted from a ll 
measuremen ts. 
TABLE l. Inhibition of prostaglandin and leukotriene synthesis and 
edema/vascular permeability 
EDoo. 11g/s ite 
Agent 
PGE, LTC./ 0, Edema/permeability 
BW755C 18 (4)" 18 (4) 44 (2) 
Indomethac in 0.4 (5) 212 (5) 14 (2) 
NDGA 285 (4) 71 (4) 21 (2) 
a The number of experiments is shown in pa rentheses. 
P reliminary histologic examination and myeloperoxidase lev-
els (an enzyme marker for polymorphonuclear cells) quanti-
tated by t he method of Bradley et al [14] revealed that few 
polymorphonuclear leukocytes (PMNL) had infiltrated into the 
tissue within t he first hour after application of 0.5 mg AA, with 
neglible immigration having occurred at t he 15 to 30-min peak 
level of metabolites (data not shown). Accumulat ion of PMNL 
in both t he vasculature and t he tissue was greater after 4 h. 
The predominant synthesis of L TC,/D 4 and not L TB4 [15, 16] 
together with t he t ime course of PMNL infiltration suggested 
t hat t hese were not the cells responsible for the conversion of 
AA to products. The AA metabolites were thus derived via 
enzymes present in a resident population of cells. 
When coapplied topically with AA, anti-inflammatory drugs 
such as BW755C, indomethacin, and NDGA inhibited the 
appearance of PGE2 and LTC4/ D4 in the t issue extracts (Fig 5, 
Table I). A lack of inhibit ion by dexamethasone (3 experiments) 
suggests t hat the metabolites arose from the applied substrate 
and not as the result of phospholipase release of endogenous 
AA. 
DISCUSSION 
Inflammation is characterized by vascular changes resu lting 
in an edematous response. A hypothesis by Williams and Peck 
[17,18] suggests that t hese vascu lar changes are t he net result 
of vasodilatation induced by protaglandins of the E series 
together with increased vascular permeability mediated by an-
other component. We have previously shown that the combi-
nation of PGE2 and polyunsaturated fatty acids that are sub-
strates for cyclooxygenase, such as linoleic acid, produce an 
edema when topically applied to mouse ears [5]. We postulated 
t hat t he oxidant derived from the cyclooxygenase oxidation 
increased vascular permeability and synergized with the vasa-
dilatory effect of PGE2 to produce the changes. Recently, LTC., 
and LTD, have been demonstrated to increase permeabi li ty of 
the vasculature of guinea pig skin and the hamster cheek pouch 
[19,20]. The present studies support a role for leukotrienes. 
The mouse ear edema caused by application of AA as described 
here may be due to synergistic effects on the blood vessels by 
the increased levels of PGE2 and L TC4/ D, found in the t issue 
extracts . 
The participation of both PGE2 and L TC,/D, in the edema 
is demonstrated by our observations: (1 ) t he time course of 
product formation precedes that of edema and increased vas-
cular permeability, the increased levels of PGE2 and L TC4/D4 
present in t he t issue may be coincident with the onset of edema; 
(2) topically applied anti- inflammatory drugs modulated levels 
of PGE2 and L TC4/ D4 which were concurrent with an inhibi-
tion of edema and vascular permeability. However, a causal 
role of either PGE2 or L TC,/ D. to mediate edema in the mouse 
ear stimulated with AA is not p roved in t hese studies . 
Compounds were demonstrated in this model to inhibit in -
flammation by biochemical and funct ional parameters. That 
both cyclooxygenase and lipoxygenase products are involved in 
the acute inflammatory response ini t iated by AA application 
may be further inferred by t he effects of 3 pharmacologic 
"standards" expressed in t he data of Table I. T he dual cycloox-
ygenase/lipoxygenase inhibitor, BW755C, modified equipo-
tently metabolite fo rmation from separate oxidative pathways 
and similarly inhibited edema and vascular permeability wit hin 
t he same range of concentrations. Coinvolvement of PGE2 and 
L TC,/D. in mediating edema may be inferred from the data 
corresponding to the effects of t he cyclooxygenase inhibitor, 
indomethacin: edema was suppressed at an intermediate dose 
level compared to PGE2 and LTC,/D4 inhibition. The antioxi-
dant lipoxygenase inhibitor, NDGA, suppressed detectable lev-
els of L TC./D, at doses by which edema and vascular permea-
bility were diminished to a similar exten t, suggesting t hat the 
role of L TC.,/D4 in inducing changes in vascular permeability 
was substant ial in effecting AA- induced mouse ear edema. 
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Recent studies by Young et al have also indicated that 
products of the 5-lipoxygenase pathway may play a role in AA-
induced inflammation [21]. Their conclusions were based on 
the inhibition of AA-induced edema by various 5-lipoxygenase 
inhibitors. Our studies complement those observations by dem-
onstrating the effects of 5-lipoxygenase inhibitors on inhibition 
of edema and on the diminished amounts of 5-lipoxygenase 
products in the inflamed tissue. Our model differs with that of 
Young et al in that indomethacin was active as an inhibitor of 
the edematous response. Measurements of substantial levels of 
PGE2 in the inflamed tissue and the diminishment of PGE2 
levels by indomethacin provided clear evidence that cyclooxy-
genase was active within our system. The discrepancy between 
our results and those of Young et a! must derive from differ-
ences in methodology: drugs were evaluated in our animal 
model after coapplication with 0.5 mg AA, while the system of 
Young et a! examined the effects of drugs applied 30 min prior 
to a challenge of 4 mg AA. Their study demonstrated that 2 mg 
of naproxen was ineffective as an inhibitor of edema caused by 
4 mg AA but was "strongly inhibitory" against 0.5 mg AA. This 
latter concentration was more appropriate for our pharmaco-
logic studies since it was found (in both systems) to fall on the 
linear portion of the dose-response curve by which AA induced 
edema and increased permeability (Fig 1) as well as increased 
synthesis of PGE2 and LTC4/D. (data not shown). The high 
doses of topically applied compounds necessary to inhibit 
edema in the study by Young et a] and the inability of some 
drugs (e.g., indomethacin and naproxen) to suppress the edema 
was probably a consequence of their routine use of higher levels 
(4 mg) of AA. 
This in vivo model provides a suitable method for evaluating 
the topical activity of anti-inflammatory agents which modu-
late AA metabolism. By the direct measurement of AA metab-
olites in inflamed tissues, the mechanism of action of inhibitory 
compounds may be further elucidated. 
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